Biogen Inc. (BIIB)
Market Cap | 19.16B |
Revenue (ttm) | 10.00B |
Net Income (ttm) | 1.53B |
Shares Out | 146.61M |
EPS (ttm) | 10.45 |
PE Ratio | 12.50 |
Forward PE | 8.48 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,242,870 |
Open | 127.50 |
Previous Close | 127.75 |
Day's Range | 127.00 - 131.26 |
52-Week Range | 110.04 - 207.59 |
Beta | 0.13 |
Analysts | Buy |
Price Target | 187.96 (+43.84%) |
Earnings Date | Jul 31, 2025 |
About AIRC
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r... [Read more]
Financial Performance
In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.
Financial StatementsAnalyst Summary
According to 27 analysts, the average rating for BIIB stock is "Buy." The 12-month stock price target is $187.96, which is an increase of 43.84% from the latest price.
News

Biogen: Strong Q2 Doesn't Change The Math On Eroding MS Portfolio
Biogen beat Q2 2025 revenue and EPS estimates, but core MS and SPINRAZA franchises continue to erode, offset only partially by new products. Launches like ZURZUVAE and LEQEMBI show promise, yet their ...
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.

Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript
Biogen Inc. (NASDAQ:BIIB) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Alisha A. Alaimo - President & Head of North America Christopher A.

Biogen raises annual profit forecast on strong demand for rare disease drugs
Biogen raised its annual profit forecast on Thursday, betting on strong demand for its rare disease drugs such as Skyclarys to offset declining sales of its older multiple sclerosis drugs.

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd.

Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds
Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years into treatment, according to new data presented at a medical meeting on Wedne...

ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a posi...

Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer's Association International Conference (AAIC), ta...

Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing
Biogen Inc. BIIB said on Monday that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park (RTP).

Biogen to invest $2 billion more in North Carolina
Drugmaker Biogen said on Monday it will invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park.

Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary
CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – today announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolin...

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
– Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – – These findings support the in...

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with ...

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
CAMBRIDGE, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will evaluate the efficac...

New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA
CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected...

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 1 study of salanersen (BIIB115/ION306), an antisense oligonucleotide (ASO) being...

Biogen: Investors Are Missing The Bigger Picture
Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market. On May 1, it released fairly strong financial results for the first quarter o...

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO st...

Biogen Inc. (BIIB) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)
Biogen Inc. (NASDAQ:BIIB) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:40 AM ET Company Participants Robin C. Kramer - Executive VP & CFO Conference Call Participants Salve...

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors.
Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI
Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see...

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
Collaboration leverages City Therapeutics' next-generation RNAi engineering technologies and Biogen's extensive drug development expertise Collaboration leverages City Therapeutics' next-generation RN...